uzansertib   Click here for help

GtoPdb Ligand ID: 10626

Synonyms: INCB-053914 | INCB053914
Compound class: Synthetic organic
Comment: Uzansertib (INCB053914) is a pan-PIM kinase inhibitor that was developed by Incyte Corporation as a novel anticancer agent [1]. The chemical structure that was submitted to the WHO for the INN uzansertib is identical to the structure of INCB053914. INCB053914 is a Type 1, ATP-competitive inhibitor. The PIMs (PIM1, PIM2, and PIM3) are serine/threonine protein kinases that are important players in JAK/STAT and PI3K/AKT signalling pathways and in tumourigenesis. PIMs are known to be overexpressed in haematologic and solid tumours, and consequently PIM inhibitors are being developed and investigated for clinical anti-tumour potential.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 124.6
Molecular weight 513.2
XLogP 2.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1CN(CC(C1O)N)c1c(cnc2c1CCC2O)NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F
Isomeric SMILES C[C@@H]1CN(C[C@@H]([C@H]1O)N)c1c(cnc2c1CC[C@@H]2O)NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F
InChI InChI=1S/C26H26F3N5O3/c1-12-10-34(11-17(30)25(12)36)24-13-5-8-20(35)22(13)31-9-19(24)33-26(37)18-7-6-16(29)23(32-18)21-14(27)3-2-4-15(21)28/h2-4,6-7,9,12,17,20,25,35-36H,5,8,10-11,30H2,1H3,(H,33,37)/t12-,17+,20+,25+/m1/s1
InChI Key PTORCEYGCGXHDH-SGQXWQAPSA-N
No information available.
Summary of Clinical Use Click here for help
INCB053914 has progressed to Phase 1/2 clinical evaluation in solid tumours (NCT02587598) and in myelodysplastic/myeloproliferative neoplasms (NCT04061421). In both of these trials INCB053914 is being tested in combination with other chemotherapy drugs.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02587598 Study of INCB053914 in Subjects With Advanced Malignancies Phase 1/Phase 2 Interventional Incyte Corporation
NCT04061421 A Basket Study of Novel Therapy for Untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes (ABNL-MARRO) Phase 1/Phase 2 Interventional Vanderbilt-Ingram Cancer Center